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Background: The effect of pro-inflammatory stimuli on bronchoconstrictor-induced air
trapping has not been studied.
Objective: To determine the effect of natural allergen exposure, a pro-inflammatory stimulus,
on methacholine- and adenosine 50-monophospate (AMP)-induced air trapping.
Methods: Airway responsiveness to methacholine and AMP before and during the pollen season
was obtained in 25 subjects with pollen allergy and in 10 healthy controls. The response was
expressed by the sensitivity (PC20 value) and by the slope and intercept of the FVC values
recorded at each step of the challenge against the corresponding FEV1 values.
Results: The slope and intercept FVC versus FEV1 values for both methacholine and AMP were
significantly higher in subjects with pollen allergy than in healthy controls. In the group with
pollen allergy, both methacholine and AMP PC20 values decreased significantly during the
pollen season. However, the mean (95% CI) slope FVC versus FEV1 values for methacholine were
1.00 (0.84e1.16) before the pollen season and 0.99 (0.86e1.12, P Z 0.90) during the pollen
season. Similar results were obtained with AMP.
Conclusions: Although the air trapping induced by both methacholine and AMP is significantly
greater in subjects with pollen allergy than in healthy controls, natural allergen exposure is asso-
ciatedwith a selective increase in airway sensitivitywithout concomitant changes in bronchocon-
strictor-induced air trapping. These findings suggest that the information provided by the
bronchoconstrictor-inducedchange inFEV1 andFVC is notequivalent andmaybecomplementary.
ª 2010 Elsevier Ltd. All rights reserved.to de Medicina, Facultad de Medicina y Odontologia, Av. Blasco Iba´n˜ez 15, 46010 Valencia, Spain.
477.
(L. Prieto).
0 Elsevier Ltd. All rights reserved.
Methacholine- and AMP-induced air trapping 857Introduction in patients with pollen-induced allergic rhinitis associatedAirway hyperresponsiveness can be defined as the tendency
of the airways to narrow too easily and too much in
response to a wide variety of provoking stimuli.1 Therefore,
airway responsiveness can be studied by constructing
concentration-response curves to pharmacological bron-
choconstrictors, and the response must be characterized by
at least two abnormalities: a leftward shift (increased
sensitivity) and an upward displacement (excessive airway
narrowing) of the dose-response curve. However, during
routine bronchoprovocation procedures, the response is
generally expressed as the provocation concentration of
agonist that caused a decrease in forced expiratory volume
in 1 s (FEV1) of 20% (PC20 or sensitivity),whereas the
potential for excessive airway narrowing is only excep-
tionally identified2e4 owing to the inherent risks of
provoking an excessive decline in FEV1.
Clinically and for research purposes, airway respon-
siveness is measured by bronchial challenge, usually with
methacholine or histamine.5 Both agonists predominantly
induce bronchoconstriction though a direct effect on
airway smooth muscle. In contrast, adenosine 50-mono-
phosphate (AMP) acts indirectly, causing primed mast cell
degranulation and the release of pro-inflammatory media-
tors (histamine and leukotrienes) with subsequent smooth-
muscle contraction.6 Since mast cells are believed to play
a predominant role in atopic asthma, the bronchial
response to AMP may be a more direct marker of allergic
airway inflammation than direct bronchoconstrictors.7,8
On the other hand, it has long been appreciated that
during bronchoconstriction induced by acetylcholine or
methacholine, residual volume (RV) increases9,10 and
forced vital capacity (FVC) decreases11 significantly. The
conventional explanation for why the FVC decreases during
induced bronchoconstriction is that change in the smooth
muscle tone causes an increase in air trapping. Assuming
that during induced bronchoconstriction total lung capacity
(TLC) remains constant,12 this air trapping could be
measured by the dose-dependent decline in FVC. Further-
more, because lung volume is a major determinant of the
bronchoconstrictor response,13 it has been suggested that
changes in FVC may give relevant additional information as
they correlate with the maximal degree of airway narrow-
ing14 and may reveal information about the underlying
asthma pathogenesis that is not apparent from the changes
in FEV1.
15 All these previous investigations were performed
with direct bronchoconstrictor agents (histamine, acetyl-
choline or methacholine), but little information is available
on AMP-induced air trapping.16
There is convincing evidence that, in sensitized subjects
with pollen-induced rhinitis or asthma, natural exposure to
pollen during the season provokes an increase in airway
responsiveness to both methacholine17,18 and AMP.19,20
However, the influence of natural antigenic exposure on
the magnitude of air trapping, as measured by the decrease
in FVC remains to be further documented.
The aim of this study was to determine the effect of
a pro-inflammatory stimulus, such as allergen exposure, on
methacholine- and AMP-induced air trapping. To this end,
we performed methacholine and AMP inhalation challengesor not with mild asthma both before and during the pollen
season.
Subjects and methods
A total of 35 subjects volunteered for this study. Twenty-
five patients with seasonal allergic rhinitis, with or without
mild asthma were recruited from the allergy clinic of our
institution. Asthma was identified by the presence of
asthmatic symptoms plus airway hyperresponsiveness with
a methacholine PC20 of less than 8 mg/ml (n Z 8) if the
FEV1/FVC was 70% or greater or an improvement of the FEV1
from predicted of 15% or greater after 200 mg of inhaled
salbutamol if the FEV1/FVC was less than 70% (n Z 2).
Subjects with allergic rhinitis were defined as those indi-
viduals with a characteristic history of seasonal rhinitis
during the pollen season and no history of asthma.
Skin-prick tests showed positive response (3 mm wheal
diameter) to grass and/or olea europea and/or parietaria
judaica pollens in all of the subjects. Seven subjects were
also sensitized to perennial allergens, although they had no
symptoms out of the pollen season. A control group of 10
healthy nonatopic subjects was also studied. These
subjects were recruited from volunteers in the laboratory
and among students. Selection criteria for this group
included no history of asthma, allergic rhinitis, atopic
eczema, or other relevant disease.
All 35 subjects were nonsmokers, had baseline FEV1
70% predicted and FEV1/FVC 60%, and no subjects had
a history of chronic bronchitis, emphysema, or respiratory
tract infections during the 4 weeks before the study. The
study protocol was approved by the local ethics committee,
and written informed consent was obtained from all the
participants.
Study design
The study was performed between January and June 2009.
Patients were first evaluated between mid-January and the
end of February (pre-seasonal evaluation), before the
pollen season had begun in Valencia, Spain. During this
period, patients had 3 laboratory visits. At the first visit, all
patients were evaluated for suitability and spirometry was
performed. At each of the next 2 visit (3e7 days apart),
spirometry and concentration-response studies with either
methacholine or AMP were performed on separate days,
with the order of challenge randomized. Patients returned
to the laboratory at the height of the pollen season
(seasonal evaluation) between April and June. During this
period, patients attended 2 laboratory visits. At each visit,
spirometry and concentration-response studies with either
methacholine or AMP were performed.
The pollen season period was estimated according to
atmospheric pollen counts obtained in the Valencia area.21
In our region, pollen counts between 27 and 60 grains/m3
for grass and between 30 and 345 grains/m3 for olea
europea were recorded from May to June. Urticaceae
(Parietaria judaica) pollen levels were high from the end of
March to the beginning of July, with pollen counts between
23 and 59 grains/m3.
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Figure 1 Regression lines between forced vital capacity
(FVC) and forced expiratory volume in 1 s (FEV1) measured
during bronchial challenge with methacholine in a patient with
pollen allergy (dashed line) and in a healthy control (solid line).
Regression lines were calculated by solving the linear model
y Z a þ bx, where a indicates the intercept and b the slope.
The slope of the regression line between FVC and FEV1 was
higher and the intercept lower in the patient with pollen
allergy due to a greater decline in FVC at each step of FEV1,
indicating, therefore, a greater increase in residual volume and
air trapping.
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Spirometry was performed using a calibrated pneumo-
tachograph (Jaeger MasterScope; Erich Jaeger, GmbH;
Wu¨rzburg, Germany) according to standardized guidelines.22
Baseline FEV1 and FVC were measured until 3 reproducible
recordings differing less than 5% were obtained. Reference
values were those of the European Community for Coal and
Steel.23
Inhalation challenge tests
Inhalation provocation tests were performed using a modi-
fication of the dosimeter method24,25 as previously repor-
ted.16 Short-acting inhaled b2-agonists were withheld for at
least 6 h before each challenge, oral antihistamines for at
least 72 h, and nasal topical corticosteroids for at least 2
weeks. No other asthma or rhinitis medications were used.
Methacholine and AMP (SigmaeAldrich Corp, St Louis, MO)
were dissolved freshly in 0.9% saline solution to produce
doubling concentration ranges of 0.39e100 mg/ml
(2e512 mMol/L) for methacholine and 6.25e1600 mg/ml
(18e4608 mMol/L) for AMP. Each solution was administered
from a jet nebulizer attached to a breath-activated
dosimeter (Mefar MB3; Mefar, Brescia, Italy) with an output
of 10 ml per breath. Patients inhaled the aerosolized
methacholine and AMP solutions in 5 inhalations from FRC
to TLC through a mouthpiece with the nose clipped. Both
FEV1 and FVC were measured 60e90 s after inhalation of
each concentration. The FVC maneuver was continued until
a plateau in the volume-time curve was achieved by visual
inspection, and the minimum duration of the FVC maneuver
was 6 s. The test was interrupted when a 20% decrease in
FEV1 from the post-saline solution administration value was
recorded or when the highest concentration was
administered.
The PC20 was calculated by means of logarithmic
interpolation.26 Occurrence of air trapping during airway
narrowing was inferred from the linear regression of the
FVC values recorded at each step of the challenge against
the corresponding FEV1 values.
27 In this analysis, the slope
and intercept of FVC versus FEV1 values quantify the
amount of air trapping associated with airway narrowing. A
low slope and a high interception indicate the occurrence
of airway narrowing with a small or no air trapping and vice
versa (Fig. 1).
Statistical analysis
The primary outcome of the study was the slope FVC versus
FEV1 for methacholine. Secondary outcomes were the
intercept FVC versus FEV1 for methacholine, slope and
intercept FVC versus FEV1 for AMP, and PC20 values. On the
basis of previous data,16,27 this study had 90% power to
detect a change of 0.23 in the slope FVC versus FEV1 at 0.05
significance.
Data were analysed using a standard statistical software
package (Instat for Windows version 3.0; GraphPad Software
Inc, San Diego, CA). All PC20 values were log-transformed
before analysis and are presented as geometric means with
95% confidence intervals (CIs). All other numerical variablesare reported as arithmetic means with 95% CIs. Comparison
of the characteristics between groups was performed using
unpaired t tests or the Fisher exact test, as appropriate.
Changes in PC20, slope and intercept FVC vs FEV1 values were
evaluatedusingpaired t testswithineachgroupandunpaired
t tests to compare differences between groups. Correlations
were evaluated using the Pearson correlation coefficient;
P values are 2-sided, andP<0.05was considered statistically
significant.
Results
The clinical and pulmonary function data for subjects with
pollen allergy and healthy volunteers are presented in
Table 1. Healthy controls were younger than patients with
pollen allergy, but the two groups were similar with regard
to sex and pulmonary function. In subjects with pollen
allergy, the FEV1 and FVC decreased from a mean value of
2.97 L (95% CI, 2.62e3.32 L) and 4.09 L (95% CI,
3.68e4.50 L), respectively, out of season to 2.95 L (95% CI,
2.61e3.29 L) and 4.02 L (95% CI, 3.63e4.42 L), respectively,
during the pollen season, although the differences were not
significant (P Z 0.67 for FEV1 and P Z 0.22 for FVC).
Methacholine and AMP sensitivity in and out of
pollen season
Methacholine and AMP PC20 values were significantly lower
(P Z 0.012 for methacholine and P Z 0.014 for AMP) in
subjects with pollen allergy during the pollen season than
that in control subjects (Table 2). Out of the pollen season,
Table 1 Subject characteristicsa.
Characteristics Pollen allergyb Healthy P
Subjects, No 25 10
Age, yr 50.7 (47.0e54.5) 32.1 (22.6e41.6) <0.01
Male/female gender, No 12/13 5/5 0.97
Duration of symptoms, yr 14.5 (10.7e18.3)
FEV1, % predicted 105.9 (99.6e112.3) 108.6 (99.1e118.1) 0.63
FVC, % predicted 121.3 (116.0e126.6) 114.9 (100.7e128.9) 0.26
Abbreviations: FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity.
a Data are presented as mean (95% CI) unless otherwise indicated.
b A total of 15 subjects had allergic rhinitis alone and 10 had concomitant asthma.
Methacholine- and AMP-induced air trapping 859methacholine PC20 values were also significantly lower in
subjects with pollen allergy than in healthy controls
(P Z 0.03), whereas AMP PC20 values were similar in the
two groups (P Z 0.16, Table 2).
In the overall group of subjects with pollen allergy, AMP
PC20 values decreased significantly (Table 2) during the
pollen season compared with the values found out of season
(PZ 0.007); the mean (95% CI) reduction was 1.4 doubling
concentrations (0.4 to 2.5 doubling concentrations).
Methacholine PC20 values were also lower during the pollen
season than out of season, but differences did not reach
statistical significance (PZ 0.07); the mean (95% CI) reduc-
tion was 0.5 doubling concentrations (1.0e0.1 doubling
concentrations). Although natural pollen exposure was
associated with greater changes in AMP PC20 than meth-
acholine PC20 values, differences did not reach statistical
significance, the mean difference being 0.9 doubling
concentrations (95% CI, 0.2e2.1 doubling concentrations,
PZ 0.09).
Methacholine- and AMP-induced air trapping in and
out of pollen season
Slope FVC versus FEV1 values for methacholine and AMP
were significantly higher in subjects with pollen allergy
than in healthy controls (Table 2) both during the pollen
season (PZ 0.0004 for methacholine and PZ 0.03 for AMP)
(Fig. 2) and out of season (PZ 0.001 for methacholine and
P Z 0.04 for AMP). Values for intercept FVC versus FEV1Table 2 Airway sensitivity and air trapping in subjects with po
Variables Pollen allergy
Out of season
PC20 methacholine,
b mg/ml 21.5 (10.5e44.2)
PC20 AMP,
b mg/ml 839.4 (481.9e1462.2)
Slope FVC versus FEV1
a
Methacholine 1.00 (0.84e1.16)
AMP 0.75 (0.59e0.92)
Intercept FVC versus FEV1,
a L
Methacholine 1.20 (0.87e1.54)
AMP 2.14 (1.58e2.70)
Abbreviations: AMP Z adenosine 50-monophosphate.
a Data are given as mean (95% confidence interval).
b Data are given as geometric mean (95% confidence interval).obtained with either methacholine or AMP were signifi-
cantly lower in subjects with pollen allergy than in healthy
controls (Table 2) both during the pollen season (P Z 0.01
for methacholine and PZ 0.02 for AMP) (Fig. 3) and out of
season (P Z 0.01 for methacholine and P Z 0.03 for AMP).
In the overall group of subjects with pollen allergy,
changes in the slope and intercept FVC versus FEV1 for
methacholine during the pollen season were not significant
(P Z 0.90 for the slope and P Z 0.60 for the intercept,
Table 2 and Fig. 4). These changes were also not significant
for AMP (P Z 0.74 for the slope and P Z 0.55 for the
intercept, Table 2 and Fig. 5). In addition, pollen-induced
change in the slope and intercept FVC versus FEV1 was
similar for both bronchoconstrictor agents, the mean
difference being 0.02 (95% CI, 0.29e0.26, PZ 0.90) for
the slope and 0.29 L (1.08e0.51 L, P Z 0.47) for the
intercept FVC versus FEV1.
Changes in the slope and intercept FVC versus FEV1
induced by natural pollen exposure were not significant in
both the 15 nonasthmatic subjects with allergic rhinitis and
the 10 subjects with mild asthma (Table 3). Pollen-induced
changes ineither the slopeand interceptFVCversusFEV1with
methacholine were not significantly different between the
group with allergic rhinitis alone and the group with mild
asthma, themeandifferencebeing 0.10 (95%CI,0.28e0.48,
P Z 0.59) for the slope and 0.07 L (95% CI, 0.34e0.47,
PZ 0.71) for the intercept. Changes in either the slope and
interception FVC versus FEV1 with AMP were also not signifi-
cantly different between the two groups, the meanllen allergy and healthy controls.
Healthy
During season
15.3 (7.1e33.0) 75.9 (53.5e107.4)
307.6 (137.4e690.2) 1563.1 (1479.2e1600.0)
0.99 (0.86e1.12) 0.52 (0.30e0.75)
0.72 (0.59e0.85) 0.44 (0.15e0.73)
1.32 (0.83e1.81) 3.46 (1.87e5.04)
1.97 (1.53e2.41) 3.94 (2.38e5.50)
a 
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Figure 2 Individual values for the slope of FVC recorded at
each step of the challenge against the corresponding FEV1
values (slope FVC versus FEV1) obtained with (a) methacholine
and (b) AMP in subjects with pollen allergy during the pollen
season and in healthy controls. Horizontal lines indicate
means.
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Figure 3 Individual values for the intercept of FVC recorded
at each step of the challenge against the corresponding FEV1
values (intercept FVC versus FEV1) obtained with (a) meth-
acholine and (b) AMP in subjects with pollen allergy during the
pollen season and in healthy controls. Horizontal lines indicate
means.
860 V. Lopez et al.difference being 0.09 (95% CI, 0.49e0.31, P Z 0.63) for
the slope and 0.06 L (95% CI, 1.29e1.40, PZ 0.93) for the
intercept.
Correlations
No significant correlation was found between the slope or
intercept FVC versus FEV1 values obtained with meth-
acholine and with AMP. Furthermore, seasonal changes in
either the slope or intercept FVC versus FEV1 with meth-
acholine and AMP were not significantly related.
Discussion
The results of the present study have confirmed that in
subjects who are pollen-sensitive and have allergic rhinitis
associated or not with mild asthma, natural exposure to
pollen increases airway sensitivity (decrease in PC20 values)
to both methacholine and AMP. The new findings are that, in
these pollen-sensitive subjects, natural pollen exposure is
not associated with significant modifications in the meth-
acholine- and AMP-induced changes in FVC, and that even
during a period of absence of natural allergen exposure, the
air trapping induced by each bronchoconstrictor agent, as
reflected by changes in FVC, is significantly greater in
subjects with pollen allergy than in healthy controls.
Furthermore, allergen-induced modifications in air trapping
in response to each agonist were not significantly related.These results suggest that airway sensitivity to direct and
indirect bronchoconstrictor agents may be increased in
response to pro-inflammatory stimuli, such as allergenic
exposure, without concomitant modifications in broncho-
constrictor-induced changes in FVC.
Earlier studies have already shown that, in subjects with
pollen-induced allergic rhinitis or asthma, natural pollen
exposure during the pollen season significantly increases
airway sensitivity to methacholine17,18 and AMP.19,20 The
present study confirms and extends these previous obser-
vations. In addition, our results demonstrate that, in this
group of subjects with pollen allergy, methacholine sensi-
tivity is significantly increased compared with healthy
controls, both during the pollen season and out of pollen
season. AMP sensitivity is also increased during the period
of natural pollen exposure, but AMP PC20 values out of the
pollen season are similar to those in healthy controls. These
findings are consistent with the suggestion that the
response to AMP may reflect acute inflammatory changes in
the bronchial mucosa, whereas methacholine responsive-
ness might be predominantly dependent on more persistent
changes on the bronchial tree.7
Our results clearly demonstrate that, in pollen-sensitive
subjects, natural allergen exposure is not associated with
modifications in the methacholine- and AMP-induced air
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Figure 5 Individual values for the (a) slopeFVCversusFEV1and
(b) intercept FVC versus FEV1 obtained with AMP before and
during the pollen season. Horizontal lines are arithmetic means.
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Figure 4 Individual values for the (a) slope FVC versus FEV1
and (b) intercept FVC versus FEV1 obtained with methacholine
before and during the pollen season. Horizontal lines are
arithmetic means.
Methacholine- and AMP-induced air trapping 861trapping, as reflected by changes in FVC. These findings
confirm and extend previous observations28 showing that, in
subjects with seasonal allergic rhinitis the mean change in
FEV1/FVC ratio at the highest methacholine concentration
was not significantly different during the pollen season and
out of season. To the best of our knowledge, however, this
is the first study designed to determine the effect of
natural allergen exposure on AMP-induced air trapping. Our
results clearly demonstrate that natural allergen exposure
is not associated with significant modifications in AMP-
induced air trapping, as reflected by changes in FVC. It has
been postulated that methacholine-induced changes in FVC
may provide information regarding excessive airway nar-
rowing14 and, therefore, the results of the present study
seem to be inconsistent with those obtained in several
previous investigations reporting that, in pollen-sensitive
subjects with allergic rhinitis or asthma, natural pollen
exposure is associated with significant increases in the
maximal degree of airway narrowing.18,29 However, we
have recently reported that in pollen-sensitive subjects
with asthma or allergic rhinitis, the maximal degree of
airway narrowing increases during the pollen season,
without concomitant modifications in bronchoconstrictor-
induced fall in FVC.30 These results suggest that the change
in FVC induced by the bronchoconstrictor agent cannot be
used as a surrogate estimation of the maximal degree of
airway narrowing. However, our results were obtained in
patients with mild asthma or allergic rhinitis without
asthma, and it could be argued that the effect of natural
allergen exposure on methacholine and AMP-induced
changes in FVC might be different in subjects with greater
asthma severity. This should be investigated in future
studies.
Although we do not believe that our findings can be
explained by measurement errors, alternative explanations
should be considered for differences in methacholine- and
AMP-induced changes in FVC between subjects with pollen
allergy and healthy controls. It is known that histamine-
induced declines in FVC are related to some extent to the
baseline airway calibre.31 Thus, the greater effect of each
bronchoconstrictor on FVC in subjects with pollen allergy
compared with healthy controls might be a consequence of
differences in baseline FEV1. However, we believe that
these results are not affected significantly by this factor
because FEV1 values in both populations were similar. In
addition, the age was significantly higher in the group with
pollen allergy than in healthy controls. Although the influ-
ence of this factor on methacholine- and AMP-induced
changes in FVC has not been investigated, we cannot reject
that differences in the FVC decline might be caused, at
least partially, by this factor.
Whywouldnatural allergenexposure significantly increase
methacholine and AMP sensitivity, but not the air trapping
induced by each agonist?. The response to this question may
be only speculative. It has been postulated that inflammatory
changes in the airways are more important in modulating the
calibre of peripheral than of central airways.15 Furthermore,
in subjectswith almost normal lung function,as in thepresent
study, the FEV1 reflects expiratory flow at high-to-mid lung
volumes, which are probably determined by the calibre of
relatively large airways, whereas the RV (and the subsequent
reduction inFVC) isprobablydeterminedbyclosureof smaller
Table 3 Pollen-induced changesa in air trapping in subjects with allergic rhinitis and in those with mild asthma.
Variables Allergic rhinitis Mild asthma
Out of season During season Out of season During season
Slope FVC vs FEV1
Methacholine 0.77 (0.54e1.00) 0.87 0.70e1.04) 1.16 (0.99e1.33) 1.16 (1.02e1.30)
AMP 0.64 (0.44e0.84) 0.61 (0.45e0.78) 0.80 (0.49e1.12) 0.87 (0.68e1.05)
Intercept FVC vs FEV1, L
Methacholine 1.98 (1.11e2.85) 1.64 (0.93e2.35) 0.92 (0.49e1.35) 0.85 (0.46e1.25)
AMP 2.60 (1.76e3.45) 2.27 (1.60e2.93) 2.05 (1.20e2.91) 1.67 (1.28e2.05)
For abbreviations see Tables 1 and 2.
a Data are presented as mean (95% confidence interval).
862 V. Lopez et al.airways.27 If these inferences are correct, the results of the
present studywould suggest that the consequences of natural
allergen exposure are predominantly expressed in large
airways.
In conclusion, this study sheds new information on the
way in which allergen exposure induces changes in airway
responsiveness of subjects with respiratory allergy. In
particular, the findings show that natural allergen exposure
is associated with a significant increase in airway sensitivity
without concomitant changes in bronchoconstrictor-
induced air trapping. These data suggest that the infor-
mation provided by the agonist-induced change in FEV1 and
FVC is not equivalent and may be complementary.Acknowledgements
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